Abstract

Non-alcoholic fatty liver disease (NAFLD) covers a spectrum of disorders ranging from simple steatosis (non-alcoholic fatty liver, NAFL) to non-alcoholic steatohepatitis (NASH) and cirrhosis. NAFL increases the risk of liver fibrosis. If the liver is fatty due to causes of insulin resistance such as obesity and physical inactivity, it overproduces glucose and triglycerides leading to hyperinsulinemia and a low high-density lipoprotein (HDL) cholesterol concentration. The latter features predispose to type 2 diabetes and cardiovascular disease (CVD). Understanding the impact of nutritional modulation of liver fat content and insulin resistance is therefore of interest for prevention and treatment of NAFLD. Hypocaloric, especially low carbohydrate ketogenic diets rapidly decrease liver fat content and associated metabolic abnormalities. However, any type of caloric restriction seems effective long-term. Isocaloric diets containing 16%–23% fat and 57%–65% carbohydrate lower liver fat compared to diets with 43%–55% fat and 27%–38% carbohydrate. Diets rich in saturated (SFA) as compared to monounsaturated (MUFA) or polyunsaturated (PUFA) fatty acids appear particularly harmful as they increase both liver fat and insulin resistance. Overfeeding either saturated fat or carbohydrate increases liver fat content. Vitamin E supplementation decreases liver fat content as well as fibrosis but has no effect on features of insulin resistance.

Highlights

  • While the PNPLA3 or TM6SF2 variants increase liver fat content and the risk of non-alcoholic steatohepatitis (NASH), they do not increase the risk of type 2 diabetes or cardiovascular disease (CVD), consistent with lack of insulin resistance

  • Studies comparing effects of different diets on liver fat content and insulin sensitivity have included a low number of subjects and lasted a maximum of six months

  • The deleterious effect of high fat seems to be due to SFAs while PUFA or MUFA containing diets may be beneficial

Read more

Summary

Introduction

While the PNPLA3 or TM6SF2 variants increase liver fat content and the risk of NASH, they do not increase the risk of type 2 diabetes or cardiovascular disease (CVD), consistent with lack of insulin resistance This implies that the objectiv9e12o8f treatment of patients with “PNPLA3 NAFLD” and TM6SF2 NAFLD’ is to prevent liver disease rather than metabolic complications. This implies that the objective of treatment of patients with “PNPLA3 NAFLD” and TM6SF2 NAFLD’ is to prevent liver disease rather than metabolic complications.

Design Cal
Effect of Different Diets on NAFLD and Insulin Sensitivity
Effect of Type of Fat on NAFLD and Insulin Sensitivity
Effect of Type of Carbohydrate on NAFLD and Insulin Sensitivity
Effect of Other Nutritional Interventions on NAFLD and Insulin Sensitivity
Mechanisms Underlying Nutritional Modulation of Liver Fat Content in Humans
Findings
Concluding Remarks
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.